Irbesartan + Ciprofibrate
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
84
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Hypertension
Conditions
Hypertension, Dyslipidemia
Trial Timeline
Feb 1, 2005 โ Aug 1, 2007
NCT ID
NCT00350038About Irbesartan + Ciprofibrate
Irbesartan + Ciprofibrate is a approved stage product being developed by Bristol Myers Squibb for Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT00350038. Target conditions include Hypertension, Dyslipidemia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00350038 | Approved | Completed |
Competing Products
20 competing products in Hypertension